Literature DB >> 29727071

Risk of Type 2 Diabetes in Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: A Nationwide Longitudinal Study.

Mu-Hong Chen1,2, Tai-Long Pan3,4,5, Ju-Wei Hsu1,2, Kai-Lin Huang1,2, Tung-Ping Su1,2,6, Cheng-Ta Li1,2, Wei-Chen Lin1,2, Shih-Jen Tsai1,2, Wen-Han Chang1, Tzeng-Ji Chen7,8, Ya-Mei Bai9,1,2.   

Abstract

BACKGROUND: Studies have suggested there is an association between attention-deficit/hyperactivity disorder (ADHD) and type 2 diabetes mellitus (DM)-related risk factors, such as obesity, hypertension, and dyslipidemia. However, the association between ADHD and type 2 DM remains unknown.
METHODS: Using the Taiwan National Health Insurance Research Database, we enrolled 35,949 adolescents and young adults with ADHD (ICD-9-CM code: 314) and 71,898 (1:2) age- and sex-matched controls from 2002 through 2009 and followed up with them until the end of 2011. Participants who developed type 2 DM during the follow-up period were identified.
RESULTS: Adolescents (hazard ratio [HR] = 2.83; 95% CI, 1.96-4.09) and young adults (HR = 3.28; 95% CI, 1.41-7.63) with ADHD had a higher risk of developing type 2 DM than did the controls after adjustment for demographic characteristics, use of ADHD medications and atypical antipsychotics, and medical comorbidities. Individuals with ADHD had a shorter mean ± SD duration between enrollment and onset of type 2 DM (3.17 ± 2.33 vs 4.08 ± 2.11 years, P = .004) during the follow-up compared with the controls. Sensitivity analyses after excluding first-year (HR = 2.36; 95% CI, 1.65-3.38) and first-3-year (HR = 1.92; 95% CI, 1.19-3.09) observation periods were consistent. Long-term use of atypical antipsychotics was associated with a higher likelihood of subsequent type 2 DM (HR = 2.82, 95% CI, 1.74-4.58). DISCUSSION: Adolescents and young adults with ADHD were more likely than non-ADHD controls to develop type 2 DM in later life. In addition, those with ADHD taking atypical antipsychotics exhibited a higher risk. Although correlation does not equal causation, our findings merit further study about the relationship between ADHD and type 2 DM. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29727071     DOI: 10.4088/JCP.17m11607

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder.

Authors:  Stephen V Faraone; Tobias Banaschewski; David Coghill; Yi Zheng; Joseph Biederman; Mark A Bellgrove; Jeffrey H Newcorn; Martin Gignac; Nouf M Al Saud; Iris Manor; Luis Augusto Rohde; Li Yang; Samuele Cortese; Doron Almagor; Mark A Stein; Turki H Albatti; Haya F Aljoudi; Mohammed M J Alqahtani; Philip Asherson; Lukoye Atwoli; Sven Bölte; Jan K Buitelaar; Cleo L Crunelle; David Daley; Søren Dalsgaard; Manfred Döpfner; Stacey Espinet; Michael Fitzgerald; Barbara Franke; Manfred Gerlach; Jan Haavik; Catharina A Hartman; Cynthia M Hartung; Stephen P Hinshaw; Pieter J Hoekstra; Chris Hollis; Scott H Kollins; J J Sandra Kooij; Jonna Kuntsi; Henrik Larsson; Tingyu Li; Jing Liu; Eugene Merzon; Gregory Mattingly; Paulo Mattos; Suzanne McCarthy; Amori Yee Mikami; Brooke S G Molina; Joel T Nigg; Diane Purper-Ouakil; Olayinka O Omigbodun; Guilherme V Polanczyk; Yehuda Pollak; Alison S Poulton; Ravi Philip Rajkumar; Andrew Reding; Andreas Reif; Katya Rubia; Julia Rucklidge; Marcel Romanos; J Antoni Ramos-Quiroga; Arnt Schellekens; Anouk Scheres; Renata Schoeman; Julie B Schweitzer; Henal Shah; Mary V Solanto; Edmund Sonuga-Barke; César Soutullo; Hans-Christoph Steinhausen; James M Swanson; Anita Thapar; Gail Tripp; Geurt van de Glind; Wim van den Brink; Saskia Van der Oord; Andre Venter; Benedetto Vitiello; Susanne Walitza; Yufeng Wang
Journal:  Neurosci Biobehav Rev       Date:  2021-02-04       Impact factor: 9.052

Review 2.  PI3Kinases in Diabetes Mellitus and Its Related Complications.

Authors:  Angelo Maffei; Giuseppe Lembo; Daniela Carnevale
Journal:  Int J Mol Sci       Date:  2018-12-18       Impact factor: 5.923

3.  The association of maternal diabetes with attention deficit and hyperactivity disorder in offspring: a meta-analysis.

Authors:  Lifeng Zhao; Xuesong Li; Guanying Liu; Baoling Han; Jian Wang; Xia Jiang
Journal:  Neuropsychiatr Dis Treat       Date:  2019-03-12       Impact factor: 2.570

4.  Attention-Deficit/Hyperactivity Disorder and Mortality Risk in Taiwan.

Authors:  Vincent Chin-Hung Chen; Hsiang-Lin Chan; Shu-I Wu; Meng Lee; Mong-Liang Lu; Hsin-Yi Liang; Michael E Dewey; Robert Stewart; Charles Tzu-Chi Lee
Journal:  JAMA Netw Open       Date:  2019-08-02

5.  Effects of 12-Week Supplementation of a Polyherbal Formulation in Old Adults with Prehypertension/Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Tian Shen; Guoqiang Xing; Jingfen Zhu; Yong Cai; Shuxian Zhang; Gang Xu; Yi Feng; Donghua Li; Jianyu Rao; Rong Shi
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-14       Impact factor: 2.629

6.  Contribution of vascular risk factors to the relationship between ADHD symptoms and cognition in adults and seniors.

Authors:  Brandy L Callahan; André Plamondon; Sascha Gill; Zahinoor Ismail
Journal:  Sci Rep       Date:  2021-12-20       Impact factor: 4.379

Review 7.  ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence.

Authors:  Sara Becker; Manu J Sharma; Brandy L Callahan
Journal:  Front Aging Neurosci       Date:  2022-01-25       Impact factor: 5.750

8.  Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States.

Authors:  Abdulkarim M Meraya
Journal:  Children (Basel)       Date:  2022-01-30

9.  The relationship between diabetes mellitus and attention deficit hyperactivity disorder: A systematic review and meta-analysis.

Authors:  Yuan Ai; Jing Zhao; Hanmin Liu; Jiao Li; Tingting Zhu
Journal:  Front Pediatr       Date:  2022-09-29       Impact factor: 3.569

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.